Skip to main content
NCBI home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1994 Sep;22(17):3556–3559.

Antithrombin III: summary of first database update.

D A Lane 1, R J Olds 1, S L Thein 1
PMCID: PMC308318  PMID: 7937056

Abstract

Antithrombin III is the most important inhibitor of coagulation proteinases such as thrombin and factor Xa. Inherited deficiency of antithrombin III is a well recognised risk factor for the early development of venous thromboembolism. The gene for antithrombin III is located at chromosome 1q 23-25 and its structural organisation has been described. A database of mutations of the antithrombin III gene has been compiled and a recent update lists 184 entries. These entries are listed according to subtype of deficiency and to nucleotide sequence number. There are 68 reports of type I 'classical' and 116 reports of type II 'variant' deficiencies. This summary considers the entries in terms of the number of unique molecular events, the nature of the genetic defects and the role of CpG dinucleotides in deficiency. Sample listings of type I and II deficiency entries are provided.

Full text

PDF
3556

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Björk I., Danielsson A., Fenton J. W., Jörnvall The site in human antithrombin for functional proteolytic cleavage by human thrombin. FEBS Lett. 1981 Apr 20;126(2):257–260. doi: 10.1016/0014-5793(81)80255-4. [DOI] [PubMed] [Google Scholar]
  2. Björk I., Jackson C. M., Jörnvall H., Lavine K. K., Nordling K., Salsgiver W. J. The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin. J Biol Chem. 1982 Mar 10;257(5):2406–2411. [PubMed] [Google Scholar]
  3. Blajchman M. A., Austin R. C., Fernandez-Rachubinski F., Sheffield W. P. Molecular basis of inherited human antithrombin deficiency. Blood. 1992 Nov 1;80(9):2159–2171. [PubMed] [Google Scholar]
  4. Blajchman M. A., Fernandez-Rachubinski F., Sheffield W. P., Austin R. C., Schulman S. Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity. Blood. 1992 Mar 15;79(6):1428–1434. [PubMed] [Google Scholar]
  5. Blombäck M., Abildgaard U., van den Besselaar A. M., Clementson K. J., Dahlbäck B., Exner T., Francis C. W., Gaffney P., Gralnick H., Hoyer L. W. Nomenclature of quantities and units in thrombosis and haemostasis (recommendation 1993). A Collaborative project of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH/SSC) and the Commission/Committee on Quantities and Units (in Clinical Chemistry) of the International Union of Pure and Applied Chemistry-International Federation of Clinical Chemistry (IUPAC-IFCC/CQU(CC)). Thromb Haemost. 1994 Mar;71(3):375–394. [PubMed] [Google Scholar]
  6. Bock S. C., Harris J. F., Schwartz C. E., Ward J. H., Hershgold E. J., Skolnick M. H. Hereditary thrombosis in a Utah kindred is caused by a dysfunctional antithrombin III gene. Am J Hum Genet. 1985 Jan;37(1):32–41. [PMC free article] [PubMed] [Google Scholar]
  7. Chowdhury V., Olds R. J., Lane D. A., Conard J., Pabinger I., Ryan K., Bauer K. A., Bhavnani M., Abildgaard U., Finazzi G. Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening. Br J Haematol. 1993 Aug;84(4):656–661. doi: 10.1111/j.1365-2141.1993.tb03142.x. [DOI] [PubMed] [Google Scholar]
  8. Daly M., Perry D. J., Harper P. L., Daly H. M., Roques A. W., Carrell R. W. Insertions/deletions in the antithrombin gene: 3 mutations associated with non-expression. Thromb Haemost. 1992 May 4;67(5):521–525. [PubMed] [Google Scholar]
  9. Erdjument H., Lane D. A., Ireland H., Di Marzo V., Panico M., Morris H. R., Tripodi A., Mannucci P. M. Antithrombin Milano, single amino acid substitution at the reactive site, Arg393 to Cys. Thromb Haemost. 1988 Dec 22;60(3):471–475. [PubMed] [Google Scholar]
  10. Erdjument H., Lane D. A., Panico M., Di Marzo V., Morris H. R. Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis. Congenital substitution of arginine 393 to cysteine in antithrombin Northwick Park and to histidine in antithrombin Glasgow. J Biol Chem. 1988 Apr 25;263(12):5589–5593. [PubMed] [Google Scholar]
  11. Hultin M. B., McKay J., Abildgaard U. Antithrombin Oslo: type Ib classification of the first reported antithrombin-deficient family, with a review of hereditary antithrombin variants. Thromb Haemost. 1988 Jun 16;59(3):468–473. [PubMed] [Google Scholar]
  12. Lane D. A., Caso R. Antithrombin: structure, genomic organization, function and inherited deficiency. Baillieres Clin Haematol. 1989 Oct;2(4):961–998. doi: 10.1016/s0950-3536(89)80054-x. [DOI] [PubMed] [Google Scholar]
  13. Lane D. A., Erdjument H., Thompson E., Panico M., Di Marzo V., Morris H. R., Leone G., De Stefano V., Thein S. L. A novel amino acid substitution in the reactive site of a congenital variant antithrombin. Antithrombin pescara, ARG393 to pro, caused by a CGT to CCT mutation. J Biol Chem. 1989 Jun 15;264(17):10200–10204. [PubMed] [Google Scholar]
  14. Lane D. A., Ireland H., Olds R. J., Thein S. L., Perry D. J., Aiach M. Antithrombin III: a database of mutations. Thromb Haemost. 1991 Dec 2;66(6):657–661. [PubMed] [Google Scholar]
  15. Lane D. A., Olds R. J., Boisclair M., Chowdhury V., Thein S. L., Cooper D. N., Blajchman M., Perry D., Emmerich J., Aiach M. Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1993 Aug 2;70(2):361–369. [PubMed] [Google Scholar]
  16. Lane D. A., Olds R. J., Conard J., Boisclair M., Bock S. C., Hultin M., Abildgaard U., Ireland H., Thompson E., Sas G. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest. 1992 Dec;90(6):2422–2433. doi: 10.1172/JCI116133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lane D. A., Olds R. R., Thein S. L. Antithrombin and its deficiency states. Blood Coagul Fibrinolysis. 1992 Jun;3(3):315–341. doi: 10.1097/00001721-199206000-00012. [DOI] [PubMed] [Google Scholar]
  18. Molho-Sabatier P., Aiach M., Gaillard I., Fiessinger J. N., Fischer A. M., Chadeuf G., Clauser E. Molecular characterization of antithrombin III (ATIII) variants using polymerase chain reaction. Identification of the ATIII Charleville as an Ala 384 Pro mutation. J Clin Invest. 1989 Oct;84(4):1236–1242. doi: 10.1172/JCI114290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Olds R. J., Lane D. A., Chowdhury V., De Stefano V., Leone G., Thein S. L. Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia. Biochemistry. 1993 Apr 27;32(16):4216–4224. doi: 10.1021/bi00067a008. [DOI] [PubMed] [Google Scholar]
  20. Olds R. J., Lane D. A., Thein S. L. The molecular genetics of antithrombin deficiency. Br J Haematol. 1994 Jun;87(2):221–226. doi: 10.1111/j.1365-2141.1994.tb04902.x. [DOI] [PubMed] [Google Scholar]
  21. Olds R. J., Lane D., Caso R., Tripodi A., Mannucci P. M., Thein S. L. Antithrombin III Milano 2: a single base substitution in the thrombin binding domain detected with PCR and direct genomic sequencing. Nucleic Acids Res. 1989 Dec 25;17(24):10511–10511. doi: 10.1093/nar/17.24.10511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Owen M. C., George P. M., Lane D. A., Boswell D. R. P1 variant antithrombins Glasgow (393 Arg to His) and Pescara (393 Arg to Pro) have increased heparin affinity and are resistant to catalytic cleavage by elastase. Implications for the heparin activation mechanism. FEBS Lett. 1991 Mar 25;280(2):216–220. doi: 10.1016/0014-5793(91)80296-f. [DOI] [PubMed] [Google Scholar]
  23. Rosenberg R. D., Damus P. S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973 Sep 25;248(18):6490–6505. [PubMed] [Google Scholar]
  24. Sas G. Hereditary antithrombin III deficiency: biochemical aspects. Haematologia (Budap) 1984;17(1):81–86. [PubMed] [Google Scholar]
  25. Sas G., Petö I., Bánhegyi D., Blaskó G., Domján G. Heterogeneity of the "classical" antithrombin III deficiency. Thromb Haemost. 1980 Jun 18;43(2):133–136. [PubMed] [Google Scholar]
  26. Stephens A. W., Thalley B. S., Hirs C. H. Antithrombin-III Denver, a reactive site variant. J Biol Chem. 1987 Jan 25;262(3):1044–1048. [PubMed] [Google Scholar]
  27. Thaler E., Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol. 1981 Jun;10(2):369–390. [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES